"Visitation restrictions are currently in place to decrease possible exposure to Coronavirus (COVID-19). Please visit our website for more information. CHI Health Nebraska Heart is dedicated to delivering high quality, compassionate care to Lincoln and nearby communities. Visit us at 7500 S 91st St or call (402) 489-6555 for more information."

During the past decade, Nebraska Heart Institute conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 21 clinical trials were completed, i.e. on average, 84% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 10 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nebraska Heart Institute" #1 sponsor was "Boston Scientific Corporation" with 15 trials, followed by "Edwards Lifesciences" with 8 trials sponsored, "Abbott Medical Devices" with 5 trials sponsored, "Ancora Heart, Inc." with 2 trials sponsored and "CVRx, Inc." with 2 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nebraska Heart Institute" #1 collaborator was "Abbott" with 1 trials as a collaborator, "Abiomed Inc." with 1 trials as a collaborator, "American College of Cardiology" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Nebraska Heart Institute" are "Heart Failure" (13 trials), "Coronary Artery Disease" (12 trials), "Aortic Stenosis" (4 trials), "Atrial Fibrillation" (3 trials) and "Symptomatic Severe Aortic Stenosis" (3 trials). Many other conditions were trialed in "Nebraska Heart Institute" in a lesser frequency.

Most popular intervention types in "Nebraska Heart Institute" are "Device" (42 trials), "Drug" (12 trials), "Other" (4 trials), "Procedure" (4 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Multiple arterial grafting" (2 trials), "Single arterial graft" (2 trials), "TAVR Implantation with SAPIEN XT" (2 trials) and "XIENCE V® Everolimus Eluting Coronary Stent" (2 trials). Other intervention names were less common.

The vast majority of trials in "Nebraska Heart Institute" are 58 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Nebraska Heart Institute". 1 are not yet recruiting, 3 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Nebraska Heart Institute, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Nebraska Heart Institute, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 29 trials that are defined as “Not Applicable".